首页> 外文期刊>Nature >The evolutionary history of lethal metastatic prostate cancer
【24h】

The evolutionary history of lethal metastatic prostate cancer

机译:致命转移性前列腺癌的进化史

获取原文
获取原文并翻译 | 示例
       

摘要

Cancers emerge from an ongoing Darwinian evolutionary process, often leading to multiple competing subclones within a single primary tumour. This evolutionary process culminates in the formation of metastases, which is the cause of 90% of cancer-related deaths. However, despite its clinical importance, little is known about the principles governing the dissemination of cancer cells to distant organs. Although the hypothesis that each metastasis originates from a single tumour cell is generally supported, recent studies using mouse models of cancer demonstrated the existence of polyclonal seeding from and interclonal cooperation between multiple subclones. Here we sought definitive evidence for the existence of polyclonal seeding in human malignancy and to establish the clonal relationship among different metastases in the context of androgen-deprived metastatic prostate cancer. Using whole-genome sequencing, we characterized multiple metastases arising from prostate tumours in ten patients. Integrated analyses of subclonal architecture revealed the patterns of metastatic spread in unprecedented detail. Metastasis-to-metastasis spread was found to be common, either through denovo monoclonal seeding of daughter metastases or, in five cases, through the transfer of multiple tumour clones between metastatic sites. Lesions affecting tumour suppressor genes usually occur as single events, whereas mutations in genes involved in androgen receptor signalling commonly involve multiple, convergent events in different metastases. Our results elucidate in detail the complex patterns of metastatic spread and further our understanding of the development of resistance to androgen-deprivation therapy in prostate cancer.%Gunes Gundem等人对人类前列腺肿瘤和它们的转移瘤的亚克隆组成进行了分析,从而确定了这些癌症的形成和扩散背后的演变史。重要的是,他们发现,转移瘤有可能被"补种"多次,从一个转移点向另一个转移点的扩散经常发生。这项研究为在肿瘤内以及原发性肿瘤和转移瘤之间存在的遗传改变和表观遗传改变的巨大多样性的根源提供了新线索,也显示了用定向药物进行癌症治疗在临床上所面临的挑战。
机译:癌症来自正在进行的达尔文进化过程,通常导致在一个原发肿瘤内形成多个竞争性亚克隆。这种进化过程最终形成转移灶,这是90%的癌症相关死亡的原因。然而,尽管其具有临床重要性,但关于控制癌细胞向远处器官传播的原理知之甚少。尽管通常支持每个转移源于单个肿瘤细胞的假说,但最近使用癌症小鼠模型的研究表明,存在来自多个亚克隆的多克隆种子以及它们之间的克隆间合作。在这里,我们寻求在人类恶性肿瘤中存在多克隆种子的确切证据,并在雄激素剥夺性转移性前列腺癌的背景下建立不同转移之间的克隆关系。使用全基因组测序,我们表征了十名患者的前列腺肿瘤引起的多处转移。对亚克隆体系结构的综合分析揭示了前所未有的详细转移转移模式。发现转移转移至转移很普遍,这是通过子代转移的denovo单克隆接种,或者在五种情况下,通过转移部位之间的多个肿瘤克隆的转移。影响肿瘤抑制基因的病变通常以单个事件发生,而参与雄激素受体信号传导的基因突变通常在不同转移灶中涉及多个会聚事件。我们的研究结果详细阐明了转移扩散的复杂模式,并进一步使我们了解了前列腺癌对雄激素剥夺疗法的耐药性。%Gunes Gundem等人对人类前列腺肿瘤和它们的转移瘤的亚克隆组成进行了分析,从而确定了这些癌症的形成和扩散背后的演变史。重要的是,他们发现,转移瘤有可能被“补种”多次,从一个转移点向另一个转移点的扩散经常发生。研究为在肿瘤内以及原发性肿瘤和转移瘤之间存在的遗传改变和表观遗传改变的巨大差异的根源提供了新的线索,也显示了用定向药物进行癌症治疗在临床上所面临的挑战。

著录项

  • 来源
    《Nature》 |2015年第7547期|353-357c3|共6页
  • 作者单位

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK,Department of Human Genetics, KU Leuven, Herestraat 49 Box 602, B-3000 Leuven, Belgium,Cancer Research UK London Research Institute, London WC2A 3LY, UK;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    Norwich Medical School and Department of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK,The Genome Analysis Centre, Norwich NR4 7UH, UK;

    Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;

    Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;

    Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;

    Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    The James Buchanan Brady Urological Institute, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA;

    Laboratory of Pathology, National Cancer Institute, National Institutes of Health, Maryland 20892, USA,Avoneaux Medical Institute, Oxford, Maryland 21654, USA;

    Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;

    University of Liverpool and HCA Pathology Laboratories, London WC1E 6JA, UK;

    Division of Genetics and Epidemiology, The Institute Of Cancer Research, London SW7 3RP, UK;

    Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge CB1 8RN, UK;

    Uro-oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK;

    Uro-oncology Research Group, Cancer Research UK Cambridge Institute, Cambridge CB2 0RE, UK,Department of Surgical Oncology, University of Cambridge, Addenbrooke's Hospital, Cambridge CB2 0QQ, UK;

    Norwich Medical School and Department of Biological Sciences, University of East Anglia, Norwich NR4 7TJ, UK,Division of Genetics and Epidemiology, The Institute Of Cancer Research, London SW7 3RP, UK;

    Division of Genetics and Epidemiology, The Institute Of Cancer Research, London SW7 3RP, UK,Royal Marsden NHS Foundation Trust, London SW3 6JJ, UK Sutton SM2 5PT, UK;

    Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    Cancer Genome Project, Wellcome Trust Sanger Institute, Hinxton CB10 1SA, UK;

    Institute of Biosciences and Medical Technology, BioMediTech, University of Tampere and Fimlab Laboratories, Tampere University Hospital, Tampere FI-33520, Finland;

  • 收录信息 美国《科学引文索引》(SCI);美国《工程索引》(EI);美国《生物学医学文摘》(MEDLINE);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-18 02:52:30

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号